These results implied that tumor-derived IL-6 blocked the differentiation of the myeloid progenitors and thus promoted the amplification and accumulation of CD11b+Gr-1−F4/80−MHC-II− e-MDSCs. This evidence concerns the gene IL6 and neoplasm.